A PRECISE, PERSONALISED
approach to fertility treatment.

VERSO SOLUTION

Our battery free uterine monitoring platform provides continuous data monitoring of real time uterine conditions.

Verso solution ANTENNA

Antenna charges and transmits data.

Verso solution Circuit

Microelectronic driving circuit controls the sensor head and data transfer.

Verso solution Sensor

Sensor head continuously monitors pH, oxygen and temperature.

VERSO SOLUTION

Our battery free uterine monitoring platform provides continuous data monitoring of real time uterine conditions.

Dissolved oxygen

Adaptation of a standard POLOGRAPHIC technique for ELECTROCHEMICAL sensing, our device uses an ULTRA-MINIATURE three electrode electrochemical cell.

A unique micro band working electrode reduces the impact of measurements on the monitored environment and OPTIMISES signal quality.

PH
Levels

Employing a unique Ruthenium Oxide miniature electrode, a solid state membrane produces direct reporting of hydrogen ion concentrations.

This provides a SENSITIVE, STABLE and LINEAR pH response.

Temperature
Measurements

Temperature measurements are carried out using a temperature sensing INTEGRATED circuit located in the device.

A miniaturised semi-conductor diode provides linear temperature response with high accuracy, offering a very high sensitivity to temperature changes and a high degree of responsiveness.

Data
Platform

Our proprietary software platform integrates with existing clinical software to store, process and surface data to fertility specialists.







More on our data

A Precise, Personalised Approach to Fertility Treatment

  1. 'Normal' ranges defines
  2. Cyclical variation monitored
  3. Individual patient data collected
  4. Fertility interventions monitored and optimised
1234
  • Daytime
  • Abnormal
  • Night time
  • Normal

Becoming the Standard of Care in Fertility Screening

54 Kols

Across 27 Countries

70% interest in collaborating for patient use

Latest Insights

The latest news, announcements, events and publications from Verso Biosense.

  • The First Clinical Study for our Device

    In May 2021, we received approval from Medicines Health products Regulatory Agency ('MHRA') for the initiation of the first clinical study for our groundbreaking uterine sensing device and biosensing data platform. 

    Read more
  • Partnering with London Women’s Clinic

    We're excited to announce our second product collaboration agreement with one of the UK’s leading fertility clinics.

    Read more
  • Verso Biosense signs agreement with Homerton University Hospital

    We are delighted to announce the signing of a product collaboration agreement with Homerton University Hospital.

    Read more
Previous
Next